NBIX vs UTHR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NBIX · Neurocrine Biosciences$150.57 ▼ 3.84%
UTHR · United Therapeutics$554.73 ▼ 0.78%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NBIX +6.6%
- UTHR +16.2%
Head to head
| Metric | NBIX | UTHR |
|---|---|---|
| Price | $150.57 | $554.73 |
| Change today | ▼ 3.84% | ▼ 0.78% |
| Market cap | $15.24B | $23.63B |
| Return, 3 months | -1.6% | +8.2% |
| Return, year to date | +6.2% | +13.8% |
| Return, 1 year | +6.2% | +16.8% |
| P/E (TTM) | 22.3 | 20.9 |
| P/B | 3.9 | 3.8 |
| P/E percentile vs own 5y | 8th | 96th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +41.2% | +4.1% |
| Net profit growth (YoY) | -1.4% | -23.6% |
| Gross margin | 97.7% | 86.3% |
| Operating margin | 24.6% | 39.4% |
| Net margin | 19.0% | 38.6% |
| Return on equity | 20.4% | 19.1% |
| Analyst target vs. price | +37.7% | +23.0% |
| Analyst buy share | 84% | 79% |
| RSI (14) | 43 | 42 |
| 30-day volatility | 50.0% | 31.9% |
| Max drawdown, 1 year | -27.2% | -20.9% |
| Trend read | Leaning bearish | Mixed |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- UTHR is the largest of the group by market value.
- UTHR has returned the most over the past year.
- UTHR carries the lowest trailing P/E.
- NBIX is growing revenue fastest.
- UTHR keeps the most profit per dollar of sales.
- UTHR has been the calmest stock over the last 30 days.